1. Bahekar RH, Jain MR, Goel A, Patel DN, Prajapati VM, Gupta AA, Jadav PA, Patel PR.. (2007) Design, synthesis, and biological evaluation of substituted-N-(thieno[2,3-b]pyridin-3-yl)-guanidines, N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidines, and N-(1H-indol-3-yl)-guanidines., 15 (9): [PMID:17339113] [10.1016/j.bmc.2007.02.029] |
2. Washburn WN.. (2009) Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2., 52 (7): [PMID:19243175] [10.1021/jm8013019] |
3. Miranda LP, Winters KA, Gegg CV, Patel A, Aral J, Long J, Zhang J, Diamond S, Guido M, Stanislaus S, Ma M, Li H, Rose MJ, Poppe L, Véniant MM.. (2008) Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity., 51 (9): [PMID:18412318] [10.1021/jm701522b] |
4. Mapelli C, Natarajan SI, Meyer JP, Bastos MM, Bernatowicz MS, Lee VG, Pluscec J, Riexinger DJ, Sieber-McMaster ES, Constantine KL, Smith-Monroy CA, Golla R, Ma Z, Longhi DA, Shi D, Xin L, Taylor JR, Koplowitz B, Chi CL, Khanna A, Robinson GW, Seethala R, Antal-Zimanyi IA, Stoffel RH, Han S, Whaley JM, Huang CS, Krupinski J, Ewing WR.. (2009) Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity., 52 (23): [PMID:19702274] [10.1021/jm900752a] |
5. Son S, Chae SY, Kim CW, Choi YG, Jung SY, Lee S, Lee KC.. (2009) Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives., 52 (21): [PMID:19827752] [10.1021/jm901153x] |
6. Ueda T, Ito T, Tomita K, Togame H, Fumoto M, Asakura K, Oshima T, Nishimura S, Hanasaki K.. (2010) Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution., 20 (15): [PMID:20576431] [10.1016/j.bmcl.2010.06.002] |
7. Unpublished dataset, |
8. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
9. Wang Y, Liu JJ, Dransfield PJ, Zhu L, Wang Z, Du X, Jiao X, Su Y, Li AR, Brown SP, Kasparian A, Vimolratana M, Yu M, Pattaropong V, Houze JB, Swaminath G, Tran T, Nguyen K, Guo Q, Zhang J, Zhuang R, Li F, Miao L, Bartberger MD, Correll TL, Chow D, Wong S, Luo J, Lin DC, Medina JC.. (2013) Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles., 4 (6): [PMID:24900707] [10.1021/ml300427u] |
10. Lorenz M, Evers A, Wagner M.. (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity., 23 (14): [PMID:23743288] [10.1016/j.bmcl.2013.05.022] |
11. Lorenz M, Evers A, Wagner M.. (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity., 23 (14): [PMID:23743288] [10.1016/j.bmcl.2013.05.022] |
12. Han J, Sun L, Chu Y, Li Z, Huang D, Zhu X, Qian H, Huang W.. (2013) Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates., 56 (24): [PMID:24308627] [10.1021/jm4017448] |
13. Yang B, Mei Y, Wang X, Deng X, Qian H, Huang W.. (2014) Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents., 73 [PMID:24384551] [10.1016/j.ejmech.2013.11.043] |
14. (2014) Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5, |
15. WHO Anatomical Therapeutic Chemical Classification, |
16. British National Formulary (72nd edition), |
17. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
18. AlNeyadi SS, Adem A, Amer N, Salem AA, Abdou IM.. (2017) Synthesis and in vitro biological evaluation of new pyrimidines as glucagon-like peptide-1 receptor agonists., 27 (22): [PMID:28988756] [10.1016/j.bmcl.2017.09.032] |
19. Evers A, Haack T, Lorenz M, Bossart M, Elvert R, Henkel B, Stengelin S, Kurz M, Glien M, Dudda A, Lorenz K, Kadereit D, Wagner M.. (2017) Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists., 60 (10): [PMID:28448133] [10.1021/acs.jmedchem.7b00174] |
20. Evers A, Bossart M, Pfeiffer-Marek S, Elvert R, Schreuder H, Kurz M, Stengelin S, Lorenz M, Herling A, Konkar A, Lukasczyk U, Pfenninger A, Lorenz K, Haack T, Kadereit D, Wagner M.. (2018) Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations., 61 (13): [PMID:29879354] [10.1021/acs.jmedchem.8b00292] |
21. Nishizawa N, Niida A, Adachi Y, Kanematsu-Yamaki Y, Masuda Y, Kumano S, Yokoyama K, Noguchi Y, Asakawa T, Hirabayashi H, Amano N, Takekawa S, Ohtaki T, Asami T.. (2017) Highly potent antiobesity effect of a short-length peptide YY analog in mice., 25 (20): [PMID:28917449] [10.1016/j.bmc.2017.08.044] |
22. Cai X, Sun L, Dai Y, Avraham Y, Liu C, Han J, Liu Y, Feng D, Huang W, Qian H.. (2018) Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity., 26 (9): [PMID:29673717] [10.1016/j.bmc.2018.04.022] |
23. Unpublished dataset, |
24. Li C, Cai X, Dai Y, Liu C, Bi X, Zhou J, Li Q, Sun L, Huang W, Hou Z, Qian H.. (2019) Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties., 27 (20): [PMID:31471103] [10.1016/j.bmc.2019.115070] |
25. Li L, Wu L, E X, Yan W, Cai X, Han J, Sun L.. (2019) Novel nonapeptide GLP (28-36) amide derivatives with improved hypoglycemic and body weight lowering effects., 27 (8): [PMID:30878191] [10.1016/j.bmc.2019.03.014] |
26. Lindfors L, Sundström L, Fröderberg Roth L, Meuller J, Andersson S, Kihlberg J.. (2020) Is GPR146 really the receptor for proinsulin C-peptide?, 30 (13): [PMID:32354568] [10.1016/j.bmcl.2020.127208] |
27. Milliken BT,Elfers C,Chepurny OG,Chichura KS,Sweet IR,Borner T,Hayes MR,De Jonghe BC,Holz GG,Roth CL,Doyle RP. (2021) Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis., 64 (2.0): [PMID:33449689] [10.1021/acs.jmedchem.0c01783] |
28. Wang P, Hill TA, Mitchell J, Fitzsimmons RL, Xu W, Loh Z, Suen JY, Lim J, Iyer A, Fairlie DP.. (2022) Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles., 65 (17.0): [PMID:35984914] [10.1021/acs.jmedchem.2c00653] |
29. Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, Bagley SW, Buckeridge C, Curto JM, Derksen DR, Dias JM, Griffor MC, Han S, Jackson VM, Landis MS, Lettiere D, Limberakis C, Liu Y, Mathiowetz AM, Patel JC, Piotrowski DW, Price DA, Ruggeri RB, Tess DA.. (2022) A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor., 65 (12.0): [PMID:35647711] [10.1021/acs.jmedchem.1c01856] |
30. European Medicines Agency, |